##plugins.themes.bootstrap3.article.main##

Background and Objective: Neutropenia that occurs after the first cycle of chemotherapy for non-Hodgkin’s Lymphoma (NHL) may predict its recurrence in the subsequent cycles. Moreover, it has also been reported to be a poor prognostic factor for the treatment outcome. Therefore, we aimed to observe the incidence of first cycle neutropenia and identify the potential risk factors for its occurrence among patients with NHL underwent chemotherapy.

Methods: A retrospective cohort was conducted in Sardjito General Hospital, Yogyakarta, Indonesia to analyze 466 subjects during 2012-2018, confirmed NHL, age 17 or older, treatment-naïve, underwent first-line chemotherapy without any previous primary GCSF prophylaxis. Relevant clinical conditions, pre-treatment laboratory parameters and treatment factors were obtained from medical records. Univariate and multivariate analysis were done using logistic regression to determine the significant factors.

Results: Among 466 NHL subjects, 241 (51.7%) received rituximab-containing regiment, with DLBCL as predominant subtype in 196 subjects (41.8%). Neutropenia occurred in 119 (25.5%; 95% CI 21.7-29.6%) of the cases, with 87 (73.2%) of them had moderate-severe neutropenia. Age older than 50 years old, use of rituximab-containing regiment, ANC ≤ 4.83×103 cells/mm3, and WBC ≤ 7.26×103 cells/mm3 were significant predisposing factors for first cycle neutropenia. A multivariate analysis showed two significant prognostic factors i.e., rituximab-containing regiment and ANC level ≤ 4.83×103 cells/mm3 with OR 2.18 (95% CI 1.38–3.43) and 2.30 (95%CI 1.49–3.57), respectively.

Conclusion: The administration of rituximab-based regimen and pre-treatment ANC ≤ 4.83×103 cells/mm3 in NHL require more attention to anticipate the occurrence of neutropenia after the first chemotherapy cycle. Further investigation is required to validate risk model and identify subgroup who benefits from early use of growth factor.

Downloads

Download data is not yet available.

References

  1. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin’s Lymphoma, N. Engl. J. Med. 1998; 339: 21–26. doi:10.1056/nejm199807023390104.
    DOI  |   Google Scholar
  2. Pfreundschuh M, Trümper L, Österborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379–391. doi:10.1016/s1470-2045(06)70664-7.
    DOI  |   Google Scholar
  3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002; 346: 235–42. doi:10.1056/nejmoa011795.
    DOI  |   Google Scholar
  4. Nadeem M, Idrees M, Khattak J, Hussain I, Amin Z, Arif S, et al. Frequency and severity of neutropenia in diffuse large B-cell non Hodgkin’s lymphoma after first cycle of chemotherapy comprising cyclophosphamide, doxorubicin, vincristine with prednisolone. J. Ayub Med. Coll. Abbottabad. 201; 23: 80–3.
     Google Scholar
  5. Pettengell R, Schwenkglenks M, Leonard R, Bosly A, Paridaens R, Constenla M, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: Results from the INC-EU prospective observational European neutropenia study. Support. Care Cancer, 2008; 16: 1299–1309. doi:10.1007/s00520-008-0430-4.
    DOI  |   Google Scholar
  6. Choi YW o, Jeong SH yu, Ahn MS u, Lee HW o, Kang SY u, Choi JH, et al. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. J. Korean Med. Sci. 2014; 29: 1493–1500. doi:10.3346/jkms.2014.29.11.1493.
    DOI  |   Google Scholar
  7. Pettengell R, Johnson HE, Lugtenburg PJ, Silvestre AS, Dührsen U, Rossi FG, et al. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support. Care Cancer. 2012; 20: 647-652. doi:10.1007/s00520-011-1306-6.
    DOI  |   Google Scholar
  8. Rabinowitz AP, Weiner NJ, Tronic BS, Fridman M, Liberman RF, Delgado DJ. Severe neutropenia in CHOP occurs most frequently in cycle 1: A predictive model. Leuk. Lymphoma. 2006; 47: 853–858. doi:10.1080/10428190500404316.
    DOI  |   Google Scholar
  9. Lyman GH, Lyman CH, Agboola O. Risk Models for Predicting Chemotherapy‐Induced Neutropenia. Oncologist. 2005; 10: 427–437. doi:10.1634/theoncologist.10-6-427.
    DOI  |   Google Scholar
  10. Silber JH, Fridman M, DiPaola RS, Erder MH, Pauly MV, Fox KR. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J. Clin. Oncol. 1998; 16: 2392–2400. doi:10.1200/jco.1998.16.7.2392.
    DOI  |   Google Scholar
  11. Clausen MR, Ulrichsen SP, Larsen TS, Poulsen CB, Tojaga S, Pedersen PT, et al. Depth of neutrophil nadir after first cycle of R-CHOP predicts outcome in diffuse large B-cell lymphoma–a nationwide population-based cohort study. Leuk. Lymphoma. 2008; 60: 1950–1957. doi:10.1080/10428194.2018.1554863.
    DOI  |   Google Scholar
  12. Jenkins P, Freeman S. Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann. Oncol. 2009; 20: 34–40. doi:10.1093/annonc/mdn560.
    DOI  |   Google Scholar
  13. Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, Dale DC. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer, 2011; 117: 1917–1927. doi:10.1002/cncr.25691.
    DOI  |   Google Scholar
  14. Yokoyama M, Kusano Y, Nishihara A, Inoue N, Nishimura N, Mishima Y, et al. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2). Support. Care Cancer. 2020; 28: 571–579. doi:10.1007/s00520-019-04802-4.
    DOI  |   Google Scholar
  15. Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, and Fridman, M., Risk of febrile neutropenia-among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk. Lymphoma. 2003; 44: 2069–2076. doi:10.1080/1042819031000119262.
    DOI  |   Google Scholar
  16. Christine G, Sukrisman L, Sutandyo N, Rumende CM. Rasio Neutrofil Limfosit sebagai Prediktor Neutropenia Akut Awitan Pertama Pascakemoterapi R-CHOP pada Pasien Diffuse Large B-cell Lymphoma. J. Penyakit Dalam Indones. 2019; 6: 115. doi:10.7454/jpdi.v6i3.340.
    DOI  |   Google Scholar
  17. Hryniuk WM, Goodyear M. The calculation of received dose intensity. J. Clin. Oncol. 1990; 8: 1935–1937. doi:10.1200/jco.1990.8.12.1935.
    DOI  |   Google Scholar
  18. Lepage E, Gisselbrecht C, Haioun C, Sebban C, Tilly H, Bosly A, et al. Prognostic significance of received relative dose intensity in non-Hodgkin’s lymphoma patients: Application to LNH-87 protocol. Ann. Oncol. 1993; 4: 651–656. doi:10.1093/oxfordjournals.annonc.a058619.
    DOI  |   Google Scholar
  19. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. National Cancer Institute. 2017.
     Google Scholar
  20. Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann. Oncol. 2010; 21: 248–251. doi:10.1093/annonc/mdq195.
    DOI  |   Google Scholar
  21. Chambers P, Jani Y, Wei L, Kipps E, Forster MD, Wong ICK. Patient factors and their impact on neutropenic events: a systematic review and meta-analysis. Support. Care Cancer. 2019; 27: 2413–2424. doi:10.1007/s00520-019-04773-6.
    DOI  |   Google Scholar
  22. Moore DC. Drug-Induced Neutropenia: A Focus on Rituximab-Induced Late-Onset Neutropenia. P T. 2016; 41: 765–768.
     Google Scholar
  23. Aguiar-Bujanda D, Blanco-Sánchez MJ, Hernández-Sosa M, Galván-Ruíz S, Hernández-Sarmiento S, Saura-Grau S, Bohn-Sarmiento U. Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma. Clin. Lymphoma Myeloma Leuk. 2015; 15: 761–765. doi:10.1016/j.clml.2015.07.635.
    DOI  |   Google Scholar
  24. The Asia-Pacific perspective: redefining obesity and its treatment, WHO/IASO/IOTF, 2000.
     Google Scholar